Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04671433 · ClinicalTrials.gov registry record · Phase 3
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
A Phase 3 study of X-Linked Retinitis Pigmentosa, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT04671433 is a Phase 3 study of X-Linked Retinitis Pigmentosa that has completed, run by Janssen Research & Development. The registered enrollment target is 105 participants, above the 45-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (133% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04671433, a Phase 3 study of X-Linked Retinitis Pigmentosa, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Conditions Studied
Interventions
- BIOLOGICAL Genetic: AAV5-hRKp.RPGR
Study Locations (20)
Other
- UZ Gent - Ghent
- Rigshospitalet Glostrup - Glostrup Municipality
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts - Paris
- Hadassah Medical Center - Jerusalem
- Azienda Ospedaliero Universitaria Careggi - Florence
- Ospedale San Paolo - Milan
- Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli - Naples
- IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS - Roma
- VUMC Amsterdam - Amsterdam
California
- Shiley Eye Institute Jacobs Retina Center - La Jolla
- Childrens Hospital - Los Angeles
- Stanford Health Care - Palo Alto
Florida
- VitreoRetinal Associates, PA - Gainesville
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Center for Celiac Research and Treatment - Boston
Michigan
- Univ of Michigan Medical Center - Ann Arbor
North Carolina
- Duke Eye Center - Durham
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04671433
The ClinicalTrials.gov registry entry for NCT04671433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (133% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with X-Linked Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Genetic: AAV5-hRKp.RPGR is the first listed.
NCT04671433 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04671433 about?
NCT04671433 is a clinical study titled "Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene". A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
What is the current status of trial NCT04671433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2020-12-04. Estimated completion is 2024-09-30.
What conditions does trial NCT04671433 study?
This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa.
What interventions are being tested in trial NCT04671433?
The interventions under investigation include: Genetic: AAV5-hRKp.RPGR (BIOLOGICAL).
Who is sponsoring clinical trial NCT04671433?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04671433 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-Linked Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
ACTIVE NOT RECRUITING · Phase 2
-
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
ACTIVE NOT RECRUITING · Phase 1
-
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.